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breast cancer is independent of p53 mutation or p53
overexpression and is associated with poor prognosis at
medium-term follow-up
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Summary Molecular and immunohistochemical studies of genetic events on chromosome 17p were prospectively compared with
conventional clinical and pathological parameters and disease behaviour at a minimum of 72 months follow-up. In a series of 91 patients with
primary operable breast cancer, 37 out of 91 (41%) patients had disease relapse and 23 out of 91 (25%) had died during the follow-up period.
Allelic imbalance at the YNZ22 locus (17p13.3), demonstrated in 33 out of 63 (52%) informative patients, was significantly associated with
disease recurrence (P < 0.01, 2 d.f. Cox analysis) and showed a trend towards impaired survival (P = 0.08, 2 d.f. Cox analysis) after a mean
follow-up of 84 months for survivors. By contrast, p53 mutation (in 10 out of 60, 17% of cancers), p53 allelic imbalance (in 23 out of 56, 41%
informative patients), p53 mRNA expression (in 47 out of 87, 54% patients), p53 mRNA overexpression (in 24 out of 87, 28%) or p53 protein
expression (detected in 25/76, 32%) were not associated with disease behaviour. There was no significant association between allelic
imbalance at YNZ22 and any abnormality of p53 DNA, RNA or protein. Allelic imbalance at 17p13.3 (YNZ22) serves as a marker of poor
prognosis in breast cancer. As yet unidentified genes on 17p13.3, distinct from and telomeric to p53, are therefore likely to be of clinical
importance in breast cancer.
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Molecular lesions involving the short arm of chromosome 17 are
among the commonest aberrations found in human breast cancer.
Up to two-thirds of tumours may show allelic imbalance at the
YNZ22 locus at 17pl3.3 (Mackay et al, 1988; Devilee et al, 1989;
Thompson et al, 1990; Chen et al, 1991; Singh et al, 1993;
Thorlacius et al, 1993; Cornelis et al, 1994; Harada et al, 1994;
Stack et al, 1995) and this finding has been associated with
markers of tumour aggression (Thompson et al, 1990; Chen et al,
1991; Merlo et al, 1992; Harada et al, 1994; Ito et al, 1995).
For the p53 gene (Hall et al, 1996) at 17pll3.1, mutation (demon-
strated at the DNA level) has been associated with poor prognosis
on 3-6 years follow-up (Andersen et al, 1993; Thorlacius et al,
1993; Elledge et al, 1994; Silvestrini et al, 1996). Furthermore, the
precise location of the mutation may add further information of
prognostic value (Bergh et al, 1995; Borressen et al, 1995) and
predict response to chemotherapy (Elledge et al, 1995; Aas et al,
1996). p53 protein expression has been identified as a predictor of
disease recurrence (Iwaya et al, 1991; Barnes et al, 1993; Friedrichs
et al, 1993; Marks et al, 1994), even for patients without nodal
involvement at the time of diagnosis (Allred et al, 1993; Barnes et
al, 1993; Silvestrini etal, 1993; MacGrogan etal, 1995) andforpoor
survival (Isola et al, 1992; Allred et al, 1993; Silvestrini et al, 1993;
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Elledge and Allred, 1994; Borg et al, 1995; MacGrogan et al, 1995;
Silvestrini et al, 1996). Although molecular lesions at p53 and at
YNZ22 loci occurindependently (Coles etal, 1990), itis notclearto
what extent allelic imbalance on chromosome 17p telomeric to the
p53 locus may reflect direct or indirect involvement of p53 itself.
However, there is increasingly strong evidence forpotential tumour-
suppressor genes telomeric to p53 (Chen et al, 1991; Thorlacius et
al, 1993; Comelis et al, 1994; Harada et al, 1994; Nagai et al, 1995;
Stack et al, 1995; Wales et al, 1995; White et al, 1996). To test the
hypothesis that allelic imbalance at YNZ22 is an independent
predictorofpoorprognosis inbreastcancerandtoexaminethe asso-
ciations between YNZ22 allelic imbalance and abnormalities of
p53, this study examined YNZ22 allelic imbalance, p53 mutation
status, p53 allelic imbalance, p53 mRNA expression, p53 immuno-
staining and clinical outcome with medium-term follow-up.
PATIENTS AND METHODS
Ninety-one female patients mean age 57 years (range 30-78 years)
at diagnosis with primary, previously untreated, breast cancer
underwent surgery. Node status was determined on axillary node
sampling or axillary clearance, with 45 out of 91 (50%) patients
node-positive and 46 node-negative on histological examination.
The oestrogen receptorcontent ofthe tumours was measuredusing
enzyme immunoassay (Abbott Lab, North Chicago, IL, USA) and
tumour oestrogen receptorprotein of20 fmol mg-' protein or more
was considered oestrogen receptor moderate or rich. Median
follow up was 84 months (range 72-95 months) or to death.
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Figure 1 YNZ22 allelic imbalance and disease recurrence in breast cancer.
Disease recurrence plotted against time since diagnosis (in months) for 91
patients with allelic imbalance (------), no allelic imbalance ( ) and
homozygotes (.- ). Disease recurrence significantly associated with
YNZ22 allelic imbalance (P= 0.008)
YNZ22 and p53 studies
Southern blots of paired blood/tumour DNAs were probed with
YNZ22, MCT35.1 and pBHp53 for p53 for allelic imbalance in
the tumour DNA (Coles et al, 1990). Screening for p53 mutations
in exons 5-9 was performed using the hydroxylamine osmium
tetroxide (HOT) technique and confirmed by direct sequencing
(Prosser et al, 1990). Northern blots of total ribonucleic acid
(RNA) were probed for p53 mRNA expression then for alpha-
actin mRNA as an internal control (Thompson et al, 1990). For
p53 protein expression, the 1801 antibody was used on Bouins-
fixed sections and DOl and D07 on conventionally fixed tissues
(Voijtesek et al, 1992). Results were scored independently by three
observers.
Statistical methods
Univariate Cox analysis was used to compare YNZ22 allele loss,
p53 allele loss, p53 mutation, p53 mRNA expression, p53 protein
expression, node status, tumour size, oestrogen receptor status (as
continuous variable), menopausal status with disease recurrence
and survival. The chi-squared test was used to compare YNZ22
allele loss with p53 allele loss, p53 mRNA expression and
oestrogen receptor protein content in the tumours.
RESULTS
Among the 91 patients examined for YNZ22 allelic imbalance, 63
out of 91 (69%) of patients were informative and in 33 out of 63
(52%) oftumours there was allelic imbalance (defined as a ratio of
greater than 2:1 in band intensity on laser densitometry). At the
p53 locus, allelic imbalance was demonstrated in 23 of 56 infor-
mative patients (41%). DNA from 60 of the 91 patients was
successfully examined for p53 mutation and mutations confirmed
in ten patients (17%). Among the 63 patients informative at the
YNZ22 locus, p53 mutation was present in ten cancers (16%),
seven of which showed allele imbalance at YNZ22.
Figure 2 YNZ22 allelic imbalance and survival in breast cancer. Survival
plotted against time since diagnosis (in months) for 91 patients with allelic
imbalance (------), no allelic imbalance ( ) and homozygotes (. -- ).
Poor survival was associated with YNZ22 allelic imbalance (P = 0.08)
p53 mRNA expression was detected in 47 out of 87 (54%)
breast cancers successfully examined and p53 mRNA overexpres-
sion (> 4 times expression in normal breast tissue) detected in
24 out of 87 (28%) cancers. p53 protein was detected immuno-
histochemically in 13 out of44 cancers (30%) using the 1801 anti-
body. In the 32 cancers examined with DOl and D07, the results
were identical with the two antibodies and p53 protein was
detected in 12 out of32 cancers. Strong staining was uniform over
cancer cells in eight cases but patchy in five, including one
cancer with positive p53 protein staining in the absence of any p53
mutation or detectable p53 mRNA expression.
YNZ22 allelic imbalance was associated with oestrogen
receptor-poor (< 20 fmol mg-' protein) tumours (chi-squared 3.8,
P = 0.05, 1 df), but not with p53 allele loss (39 patients informa-
tive atboth YNZ22 and p53 loci) nor with p53 expression ateither
RNA or protein level.
After a minimum of 72 months follow-up 37 out of 91 (41%)
patients had developed recurrent disease and 23 out of91 (25%) of
these patients had died.
Using univariate Cox analysis, YNZ22 allelic imbalance was
significantly associated with disease recurrence (P = 0.008; Figure
1), as were axillary node metastasis detected atdiagnosis (P < 0.001)
and tumour size (P<0.001). YNZ22 allelic imbalance was also
associated with reduced survival (P = 0.08; Figure 2) and axillary
node metastasis (P <0.001), tumour size (P = 0.008) and low
oestrogen receptor (P=0.001) were each significantly associated
with poor survival. No other parametermeasured (p53 mutation, p53
allelic imbalance, p53 mRNA expression or overexpression, p53
protein expression, age at diagnosis or menopausal status) was
significantly associated with disease recurrence or survival.
DISCUSSION
This prospective study has demonstrated that allelic imbalance at
the YNZ22 locus is significantly associated with disease recur-
rence and associated with reduced survival after medium-term
follow-up.
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YNZ22 allelic imbalance reported in this study (52%) lies
within the range (37-65%) previously published by other groups
(Chen et al, 1991; Singh et al, 1993; Thorlacius et al, 1993;
Comelis et al, 1994; Harada et al, 1994; Ito et al, 1995; Stack et al,
1995). The proportion of cancers with p53 mutation (20%), p53
allele loss (41%), p53 mRNA expression (54%) and overexpres-
sion (28%) or p53 protein expression (32%) are similar to the
reported series (Cattoretti et al, 1988; Davidoff, 1991; Iwaya,
1991; Kovach et al, 1991; Osborne et al, 1991; Runnebaum et al,
1991; Varley et al, 1991; Vojtesek et al, 1992; Andersen et al,
1993; Barnes, 1993; Friedrichs, 1993; Martinazzi, 1993;
Thorlacius et al, 1993; Tsuda et al, 1993; Elledge andAllred, 1994;
Marks et al, 1994; Bergh et al, 1995; Borressen et al, 1995;
Stenmark-Askmalm et al, 1995).
Although YNZ22 allelic imbalance may occur in the same
tumour as p53 mutation (Chen et al, 1991; Cornelis et al, 1994;
seven out of ten patients in this study) it is clearly no longer
tenable to suggest that YNZ22 allelic imbalance occurs only in the
presence of p53 mutation (Singh et al, 1993) and the two may in
fact be quite dissociated (Chen et al, 1996).
The associations between YNZ22 allelic imbalance, disease
recurrence and death due to breast cancer with medium-term
follow-up provides confirmation of the hypothesis that YNZ22
allelic imbalance was likely to be associated with poor prognosis
(Thompson et al, 1990; Nagai et al, 1995). Thus, the associations
between YNZ22 allelic imbalance and a high proliferation index
(Chen et al, 1991; Merlo etal, 1992), DNA aneuploidy (Chen et al,
1991), with absence ofprogesterone receptor expression (Ito et al,
1995), low oestrogen receptor expression (Thompson et al, 1990)
and the presence of axillary lymph node metastasis at the time of
diagnosis (Takhita et al, 1992; Harada et al, 1994) have now been
supported in this study by prospective patient follow-up beyond
6 years. In addition to the evidence presented here of a gene or
genes from 17pl3.3 associated with disease recurrence and poor
prognosis in breast cancer, this gene(s) is also implicated in
neoplastic proliferation even at the early stages ofbreast carcino-
genesis, including atypical ductal hyperplasia (Lakhani etal, 1995)
and ductal carcinoma in situ (Radford et al, 1993; Harada et al,
1994; Munn et al, 1996). Whether the gene marked by YNZ22
behaves as a tumour-suppressor gene involved in the control of
tumour cell proliferation (Merlo et al, 1992) or has a role in
promoting metastasis to lymph nodes (Harada et al, 1994), or in
some way directly or indirectly regulates p53 gene expression
(Coles et al, 1990; Chen et al, 1991) remains to be seen. It is
possible that the influence ofa gene at 17pll3.3 may be to stabilize
p53 protein and hence account for the disparity between p53
protein expression and the detection ofp53 mutations at the DNA
level (Thompson et al, 1992; Cornelis et al, 1994). However, the
function ofthe putative gene(s) at 17p13.3 remains speculative.
In the same cohort of patients that has provided evidence that
YNZ22 may mark a region of clinical importance, as in two
previous studies (Poller et al, 1992; Bland et al, 1995), we have
failed to confirm that p53 abnormalities including p53 mutation
were closely associated with disease behaviour. This may be due to
the comparatively small numbers in the present study or because
the association between p53 and prognosis in breast cancer may be
comparatively weak (Elledge and Allred, 1994; Bland et al, 1995)
or reflect the relationship between p53 and several prognostic
factors that indicate an aggressive, rapidly proliferating tumour
with an unstable genome (Stenmark-Askmalm et al, 1995). Given
that YNZ allele imbalance is more common than p53 mutation in
breast cancer, the independence of YNZ22 allele imbalance from
any p53 changes suggests that the greater discriminatory power of
the YNZ22 locus as a marker for disease behaviour is not simply
due to chance. Emerging mapping data for 17pl3.3 (Stack et al,
1995; White et al, 1996) have suggested two regions: YNZ22 and
a more telomeric region (defined by markers D17S926, D17S695,
D17S849) may be of interest in human breast cancer. Alongside
the HIC-1 (hypermethylated in cancer), ABR and CRK genes
(Heisterkamp et al, 1989; Morris et al, 1995; Wales et al, 1995) in
this region, 17pl3.3 may carry a gene or genes of both scientific
interest and clinical importance in breast cancer.
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